Cancer Family
Childhood Neoplasm
CI-CAN-00000009Explore in graph →
PediatricNon-malignant313 active trials1 approved drugs68 evidence items
- NCIt
- C6283
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000009Explore in graph →
Clinical trials
1,504 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00638898 | Busulfan, Melphalan, Topotecan Hydrochloride, and a Stem Cell Transplant in Treating Patients With Newly Diagnosed or Relapsed Solid Tumor | completed | Phase 1 | 25 | City of Hope Medical CenterOTHER | 1 | Mar 20, 2025 | clinicaltrials |
| NCT04239040 | GVAX Plus Checkpoint Blockade in Neuroblastoma | terminated | Phase 1 | 19 | Dana-Farber Cancer InstituteOTHER | 1 | Mar 19, 2025 | clinicaltrials |
| NCT06871527 | Fruquintinib Combined With PD-1 Inhibitor and FOLFOX as First-Line Treatment For Advanced Gastric Cancer | not yet recruiting | Phase 1 / Phase 2 | 44 | Sixth Affiliated Hospital, Sun Yat-sen UniversityOTHER | 1 | Mar 12, 2025 | clinicaltrials |
| NCT04023669 | Evaluation of LY2606368 Therapy in Combination With Cyclophosphamide or Gemcitabine for Children and Adolescents With Refractory or Recurrent Group 3/Group 4 or SHH Medulloblastoma Brain Tumors | completed | Phase 1 | 21 | St. Jude Children's Research HospitalOTHER | 1 | Feb 7, 2025 | clinicaltrials |
| NCT02323880 | Selinexor in Treating Younger Patients With Recurrent or Refractory Solid Tumors or High-Grade Gliomas | completed | Phase 1 | 59 | Children's Oncology GroupNETWORK | 1 | Jan 14, 2025 | clinicaltrials |
| NCT02975882 | Nanoparticle Albumin-Bound Rapamycin, Temozolomide, and Irinotecan Hydrochloride in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors | completed | Phase 1 | 33 | Children's Oncology GroupNETWORK | 1 | Jan 14, 2025 | clinicaltrials |
| NCT06760117 | UGT1A1 Genotype-drien Phase I Study of Irinotecan in VIT Regimen for the Treatment of Pediatric R/R Solid Tumors | recruiting | Phase 1 | 39 | Sun Yat-sen UniversityOTHER | 1 | Jan 6, 2025 | clinicaltrials |
| NCT02076906 | MR-guided High Intensity Focused Ultrasound (HIFU) on Pediatric Solid Tumors | completed | Phase 1 | 7 | AeRang KimOTHER | 1 | Jan 1, 2025 | clinicaltrials |
| NCT01130077 | A Pilot Study of Glioma Associated Antigen Vaccines in Conjunction with Poly-ICLC in Pediatric Gliomas | completed | Phase 1 | 60 | James FelkerOTHER | 1 | Dec 6, 2024 | clinicaltrials |
| NCT06420076 | Sequential CAR-T Cells Therapy for CD5/CD7 Positive T-cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma Using CD5/CD7-Specific CAR-T Cells(BAH246) | recruiting | Phase 1 / Phase 2 | 60 | Essen BiotechOTHER | 1 | Nov 12, 2024 | clinicaltrials |
| NCT04525014 | RRx-001 Given With Irinotecan and Temozolomide for Pediatric Patients With Recurrent or Progressive Malignant Solid and Central Nervous System Tumors(PIRATE) | terminated | Phase 1 | 2 | EpicentRx, Inc.INDUSTRY | 1 | Oct 31, 2024 | clinicaltrials |
| NCT03936465 | Study of the Bromodomain (BRD) and Extra-Terminal Domain (BET) Inhibitors BMS-986158 and BMS-986378 in Pediatric Cancer | completed | Phase 1 | 41 | Dana-Farber Cancer InstituteOTHER | 2 | Oct 2, 2024 | clinicaltrials |
| NCT03879512 | Autologous Dendritic Cells, Metronomic Cyclophosphamide and Checkpoint Blockade in Children With Relapsed HGG | completed | Phase 1 / Phase 2 | 24 | Wuerzburg University HospitalOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT05569512 | Uproleselan With Pre-Transplant Conditioning in Hematopoietic Stem Cell Transplantation for AML | terminated | Phase 1 | 1 | Malika KapadiaOTHER | 1 | Aug 19, 2024 | clinicaltrials |
| NCT05622591 | ELU001 in Pediatric Subjects Who Have Relapsed and/or Refractory CBFA2T3-GLIS2-positive AML(Pediatric AML) | withdrawn | Phase 1 | 0 | Elucida OncologyINDUSTRY | 0 | Aug 7, 2024 | clinicaltrials |
| NCT06044142 | Curcumin VS Photo-bio-modulation Therapy of Oral Mucositis in Pediatric Patients Undergoing Anti-Cancer Non-invasive Treatment | completed | Phase 1 | 90 | Riyadh Elm UniversityOTHER | 1 | Aug 5, 2024 | clinicaltrials |
| NCT03676504 | Treatment of Patients With Relapsed or Refractory CD19+ Lymphoid Disease With T Cells Expressing a Third-generation CAR | recruiting | Phase 1 / Phase 2 | 68 | University Hospital HeidelbergOTHER | 1 | Jul 29, 2024 | clinicaltrials |
| NCT05620862 | Phase I Dose Escalation and Pharmacokinetics Clinical Trial of Mitoxantrone Hydrochloride Liposome in Children With Relapsed and Refractory Lymphoma and Solid Tumors | unknown | Phase 1 | 68 | Sun Yat-sen UniversityOTHER | 1 | Jul 9, 2024 | clinicaltrials |
| NCT06456892 | Effectiveness of Pucotenlimab Combined With Standard Chemotherapy Regimen | recruiting | Phase 1 / Phase 2 | 82 | Sun Yat-sen UniversityOTHER | 1 | Jun 13, 2024 | clinicaltrials |
| NCT02061800 | CD34+ (Malignant) Stem Cell Selection for Patients Receiving Allogenic Stem Cell Transplant | unknown | Phase 1 / Phase 2 | 14 | Diane GeorgeOTHER | 1 | Jun 4, 2024 | clinicaltrials |
| NCT03434262 | SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors | completed | Phase 1 | 68 | St. Jude Children's Research HospitalOTHER | 1 | May 31, 2024 | clinicaltrials |
| NCT03206021 | COZMOS:Phase I/Ib Trial of Combined 5'Azacitidine and Carboplatin for Recurrent/Refractory Pediatric Brain/Solid Tumors(COZMOS) | completed | Phase 1 | 31 | The Hospital for Sick ChildrenOTHER | 3 | Apr 5, 2024 | clinicaltrials |
| NCT00019630 | Liposomal Doxorubicin in Treating Children With Refractory Solid Tumors | completed | Phase 1 | — | National Cancer Institute (NCI)NIH | 1 | Mar 4, 2024 | clinicaltrials |
| NCT04341311 | Phase I Study of Marizomib + Panobinostat for Children With DIPG(DIPG) | terminated | Phase 1 | 4 | Dana-Farber Cancer InstituteOTHER | 1 | Feb 15, 2024 | clinicaltrials |
| NCT03964259 | Reduced IV Fluids to Improve Clearance of HDMTX in Children w/Lymphoma or Acute Lymphoblastic Leukemia | completed | Phase 1 | 10 | Virginia Commonwealth UniversityOTHER | 1 | Feb 13, 2024 | clinicaltrials |
| NCT01606878 | Crizotinib and Combination Chemotherapy in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma | completed | Phase 1 | 46 | Children's Oncology GroupNETWORK | 2 | Jan 5, 2024 | clinicaltrials |
| NCT02808650 | Prexasertib in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors | completed | Phase 1 | 30 | Children's Oncology GroupNETWORK | 1 | Dec 20, 2023 | clinicaltrials |
| NCT00540995 | Busulfan, Etoposide, and Intensity-Modulated Radiation Therapy Followed By Donor Stem Cell Transplant in Treating Patients With Advanced Myeloid Cancer | terminated | Phase 1 / Phase 2 | 25 | City of Hope Medical CenterOTHER | 1 | Nov 30, 2023 | clinicaltrials |
| NCT00167219 | Stem Cell Transplant for Juvenile Myelomonocytic Leukemia (JMML) | completed | Phase 1 / Phase 2 | 15 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Nov 7, 2023 | clinicaltrials |
| NCT04167618 | 177Lu-DTPA-Omburtamab Radioimmunotherapy for Recurrent or Refractory Medulloblastoma | terminated | Phase 1 / Phase 2 | 2 | Y-mAbs TherapeuticsINDUSTRY | 5 | Oct 6, 2023 | clinicaltrials |
| NCT00138216 | Temozolomide, Vincristine, and Irinotecan in Treating Young Patients With Refractory Solid Tumors | completed | Phase 1 | 42 | Children's Oncology GroupNETWORK | 2 | Oct 2, 2023 | clinicaltrials |
| NCT02095132 | Adavosertib and Irinotecan Hydrochloride in Treating Younger Patients With Relapsed or Refractory Solid Tumors | completed | Phase 1 / Phase 2 | 76 | National Cancer Institute (NCI)NIH | 2 | Sep 26, 2023 | clinicaltrials |
| NCT03709914 | PK Study of Single-Dose ZTI-01 in Children (<12 Years of Age)(Pediatric_PK) | unknown | Phase 1 | 21 | Nabriva Therapeutics AGINDUSTRY | 1 | Sep 15, 2023 | clinicaltrials |
| NCT02642965 | Liposome-encapsulated Daunorubicin-Cytarabine, Fludarabine Phosphate, Cytarabine, and Filgrastim in Treating Younger Patients With Relapsed or Refractory Acute Myeloid Leukemia | completed | Phase 1 / Phase 2 | 38 | Children's Oncology GroupNETWORK | 2 | Sep 8, 2023 | clinicaltrials |
| NCT02536183 | A Phase I Study of Lyso-thermosensitive Liposomal Doxorubicin and MR-HIFU for Pediatric Refractory Solid Tumors | terminated | Phase 1 | 2 | AeRang KimOTHER | 1 | Aug 29, 2023 | clinicaltrials |
| NCT00788125 | Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors | terminated | Phase 1 / Phase 2 | 7 | City of Hope Medical CenterOTHER | 1 | Jul 14, 2023 | clinicaltrials |
| NCT05077423 | A Phase 1 Trial of CD33xCD3 BsAb in Pediatric Patients With Relapsed or Refractory Acute Myeloid Leukemia | terminated | Phase 1 | 3 | Y-mAbs TherapeuticsINDUSTRY | 1 | May 30, 2023 | clinicaltrials |
| NCT05487651 | Allogeneic NK T-Cells Expressing CD19 Specific CAR in B-Cell Malignancies(ANCHOR2) | unknown | Phase 1 | 36 | Athenex, Inc.INDUSTRY | 1 | May 18, 2023 | clinicaltrials |
| NCT03705507 | International Trial of Selumetinib in Combination With Dexamethasone for the Treatment of Acute Lymphoblastic Leukaemia(SeluDex) | terminated | Phase 1 / Phase 2 | 12 | University of BirminghamOTHER | 3 | May 11, 2023 | clinicaltrials |
| NCT02444546 | Wild-Type Reovirus in Combination With Sargramostim in Treating Younger Patients With High-Grade Relapsed or Refractory Brain Tumors | completed | Phase 1 | 6 | Mayo ClinicOTHER | 1 | Apr 24, 2023 | clinicaltrials |
| NCT03467256 | CD19 T-CAR for Treatment of Children and Young Adults With r/r B-ALL | unknown | Phase 1 / Phase 2 | 18 | Federal Research Institute of Pediatric Hematology, Oncology and ImmunologyOTHER | 1 | Feb 24, 2023 | clinicaltrials |
| NCT03825367 | Nivolumab in Combination With 5-azacytidine in Childhood Relapsed/Refractory AML | unknown | Phase 1 / Phase 2 | 13 | Therapeutic Advances in Childhood Leukemia ConsortiumOTHER | 1 | Oct 12, 2022 | clinicaltrials |
| NCT03455140 | A Study Evaluating the Safety and Activity of Pegylated Recombinant Human Arginase (BCT-100)(PARC) | completed | Phase 1 / Phase 2 | 49 | University of BirminghamOTHER | 3 | Sep 2, 2022 | clinicaltrials |
| NCT01061411 | Dalteparin and Sunitinib Malate as First-Line Therapy in Treating Patients With Kidney Cancer That is Metastatic or Cannot Be Removed by Surgery | completed | Phase 1 | 16 | Roswell Park Cancer InstituteOTHER | 2 | Aug 5, 2022 | clinicaltrials |
| NCT01640301 | Laboratory-Treated T Cells in Treating Patients With High-Risk Relapsed Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia Previously Treated With Donor Stem Cell Transplant | terminated | Phase 1 / Phase 2 | 47 | Fred Hutchinson Cancer CenterOTHER | 1 | Jul 14, 2022 | clinicaltrials |
| NCT00061945 | Alemtuzumab and Combination Chemotherapy in Treating Patients With Untreated Acute Lymphoblastic Leukemia | completed | Phase 1 / Phase 2 | 302 | National Cancer Institute (NCI)NIH | 1 | May 3, 2022 | clinicaltrials |
| NCT02415153 | Pomalidomide in Treating Younger Patients With Recurrent, Progressive, or Refractory Central Nervous System Tumors | completed | Phase 1 | 29 | National Cancer Institute (NCI)NIH | 1 | Apr 25, 2022 | clinicaltrials |
| NCT04888468 | Phase I Study of pCAR-19B in the Treatment of CD19-positive Relapsed/Refractory B-ALL in Children and Adolescents | completed | Phase 1 | 9 | Chongqing Precision Biotech Co., LtdINDUSTRY | 1 | Mar 18, 2022 | clinicaltrials |
| NCT04604691 | Blinatumomab in Pediatric B-cell Acute Lymphoblastic Leukemia (ALL) With Minimal Residual Disease (MRD) | unknown | Phase 1 | 20 | Seoul National University HospitalOTHER | 1 | Mar 8, 2022 | clinicaltrials |
| NCT01780662 | Brentuximab Vedotin and Gemcitabine Hydrochloride in Treating Younger Patients With Relapsed or Refractory Hodgkin Lymphoma | completed | Phase 1 / Phase 2 | 46 | National Cancer Institute (NCI)NIH | 2 | Oct 28, 2021 | clinicaltrials |
Data updated 23 days agoSource updated Mar 20, 2025source: clinicaltrials